Gene: USP49

25862
-
ubiquitin specific peptidase 49
protein-coding
6p21.1
Ensembl:ENSG00000164663 Vega:OTTHUMG00000014688 UniprotKB:Q70CQ1
NC_000006.12
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.620e-1 (AD)  2.492e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MPHOSPH90.874
MLLT100.872
UBN20.868
ZNF8410.866
KMT2A0.865
RNPC30.863
ZFC3H10.863
RBM330.863
NKTR0.858
DMTF10.858

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.39
PLA2G5-0.389
OR4F29-0.384
SLC22A6-0.299
S100A1-0.299
BCL7C-0.294
VAX2-0.291
RBP1-0.287
NKX6-1-0.275
PINLYP-0.273

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of USP49 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of USP49 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of USP49 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of USP49 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of USP49 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of USP49 mRNA17562736
C006780bisphenol Abisphenol A results in decreased expression of USP49 mRNA25181051
C584509C646 compoundC646 compound results in increased expression of USP49 mRNA26191083
D003300Copper[NSC 689534 binds to Copper] which results in increased expression of USP49 mRNA20971185
D004041Dietary FatsDietary Fats results in increased expression of USP49 mRNA25016146
C118739entinostatentinostat results in decreased expression of USP49 mRNA26272509
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of USP49 mRNA23649840
D005557FormaldehydeFormaldehyde results in increased expression of USP49 mRNA23649840
D006830Hydralazine[Hydralazine co-treated with Valproic Acid] results in increased expression of USP49 mRNA17183730
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of USP49 mRNA21179406
C492448ICG 001ICG 001 affects the expression of USP49 mRNA26191083
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of USP49 mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of USP49 mRNA23649840
C558013NSC 689534[NSC 689534 binds to Copper] which results in increased expression of USP49 mRNA20971185
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of USP49 mRNA26272509
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of USP49 mRNA"25510870
C046012pentanalpentanal results in decreased expression of USP49 mRNA26079696
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of USP49 mRNA26272509
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of USP49 mRNA19710929
D011374ProgesteroneProgesterone results in decreased expression of USP49 mRNA19690047
D011441PropylthiouracilPropylthiouracil results in decreased expression of USP49 mRNA24780913
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of USP49 mRNA23806026
D012999SomanSoman results in increased expression of USP49 mRNA19281266
D000952Antigens, Polyomavirus Transforming"Antigens, Polyomavirus Transforming results in increased expression of USP49 mRNA"26680231
D013849ThimerosalThimerosal results in decreased expression of USP49 mRNA27188386
C483909torcetrapibtorcetrapib results in increased expression of USP49 mRNA23228038
D014212TretinoinTretinoin results in decreased expression of USP49 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
C012589trichostatin Atrichostatin A affects the expression of USP49 mRNA28542535
C012589trichostatin Atrichostatin A results in decreased expression of USP49 mRNA24935251|2627250
D014635Valproic Acid[Hydralazine co-treated with Valproic Acid] results in increased expression of USP49 mRNA17183730
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of USP49 mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of USP49 mRNA17292431
D001335Vehicle EmissionsVehicle Emissions affects the methylation of USP49 gene25560391
C111237vorinostatvorinostat results in decreased expression of USP49 mRNA26272509|2718838

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004197cysteine-type endopeptidase activity-IMP23824326  
GO:0004843thiol-dependent ubiquitin-specific protease activity-IDA14715245  23824326  
GO:0005515protein binding-IPI19615732  23824326  25036637  
GO:0008270zinc ion binding-IEA-  
GO:0036459thiol-dependent ubiquitinyl hydrolase activity-IDA23824326  
GO:0036459thiol-dependent ubiquitinyl hydrolase activity-TAS-  
GO:0042393histone binding-IDA23824326  
GO ID GO Term Qualifier Evidence PubMed
GO:0000398mRNA splicing, via spliceosome-IMP23824326  
GO:0006511ubiquitin-dependent protein catabolic process-IEA-  
GO:0016579protein deubiquitination-IDA14715245  
GO:0016579protein deubiquitination-TAS-  
GO:0035616histone H2B conserved C-terminal lysine deubiquitination-IDA23824326  
GO ID GO Term Qualifier Evidence PubMed
GO:0005654nucleoplasm-TAS-  
GO:0005737cytoplasm-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-392499Metabolism of proteinsTAS
R-HSA-5688426DeubiquitinationTAS
R-HSA-5689880Ub-specific processing proteasesTAS
R-HSA-597592Post-translational protein modificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29133146Association of genetic polymorphisms with erythrocyte traits: Verification of SNPs reported in a previous GWAS in a Japanese population. (2018 Feb 5)Seiki TGene